作者
Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, Kei Kunimasa, Shiro Fujita, Reiko Kaji, Kenji Notohara, Yukihiro Imai, Ryo Tachikawa, Keisuke Tomii, Yohei Korogi, Masahiro Iwasaku, Akihiro Nishiyama, Tadashi Ishida
发表日期
2013/1/1
期刊
Journal of Thoracic Oncology
卷号
8
期号
1
页码范围
89-95
出版商
Elsevier
简介
Introduction
Epidermal growth factor receptor (EGFR) mutations are found mostly in adenocarcinoma, and rarely in squamous cell carcinoma (SQC). Little is known about SQC harboring EGFR mutations.
Methods
Between April 2006 and October 2010, we investigated the incidence of EGFR activating mutations in SQC of the lung using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method. The efficacy of EGFR-tyrosine kinase inhibitors (TKIs) was retrospectively evaluated in patients with EGFR-mutated SQC. Further pathologic analyses were performed using immunohistochemistry.
Results
Thirty-three of 249 patients with SQC (13.3%) had EGFR mutations, including exon 19 deletion (19 of 33 patients, 58%), L858R point mutation in exon 21 (12 of 33, 36%), and G719S point mutation in exon 18 (2 of 33, 6%). Twenty of these 33 patients received EGFR-TKI therapy, and five of these …
学术搜索中的文章
A Hata, N Katakami, H Yoshioka, K Kunimasa, S Fujita… - Journal of Thoracic Oncology, 2013